• Biophan Technologies(West Henrietta, New York) reported results from testing of the company’s technology that will enable MRI within vascular stents, allowing physicians for the first time to assess the health of stented arteries by means of non-invasive MRI technology. Currently, evaluation of restenosis within a stent requires an additional interventional procedure, and both of these procedures require the insertion of a catheter and guidewire into the patient. Biophan’s technology to enable MR imaging within a stent would allow a non-invasive diagnostic procedure to provide similar data, eliminating the need for catheterization of the patient, exposure of the patient to ionizing radiation to obtain the X-ray image, and exposure of the patient to contrast agents. The technology employs the company’s “active” MRI solutions, which it said use proprietary resonant frequency circuitry to enable superior visualization within an MRI.

• Bruker Daltonics (Billerica, Massachusetts) said its new ClinProt Micro solution is being showcased at this week’s American Association for Cancer Research meeting in Ana-heim, California. The company said the ClinProt Micro is an easy-to-use and compact clinical system dedicated to peptide and protein profiling, biomarker discovery and biomarker validation (currently for research use only). It is based on a high-performance bench-top MALDI-TOF mass spectrometer from Bruker Daltonics’ FLEX series, providing the reliability and reproducibility needed for rigorous validation studies of putative biomarkers for cancer and other diseases. The ClinProt Micro system offers integrated sample preparation tools for biofluids and tissue extracts with comprehensive analysis, visualization and model-building software.